CDX2 and colorectal carcinoma: Given that CDX2 is a recently identified biomarker, its clinical efficacy is still being explored, and the immunohistochemical scoring methods utilized to evaluate its expression in CRC employ cut-off criteria, resulting in semi-quantitative findings with varying expression percentages and discrepancies regarding its correlation with other clinicopathological and molecular parameters, as indicated by studies investigating this biomarker [9].